Clinical and Translational Science Institute

Centers

12-1-2018

Predictors of Major Bleeding Among Working-Age Adults with
Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug
Interactions and Switching from Warfarin to Non-vitamin K Oral
Anticoagulants
Xue Feng
West Virginia University

Usha Sambamoorthi
West Virginia University

Kim Innes
West Virginia University

Gregory Castelli
University of Pittsburgh

Traci LeMasters
West Virginia University
Follow this and additional works at: https://researchrepository.wvu.edu/ctsi

SeePart
nextof
page
additional
the for
Medicine
and authors
Health Sciences Commons

Digital Commons Citation
Feng, Xue; Sambamoorthi, Usha; Innes, Kim; Castelli, Gregory; LeMasters, Traci; Xiong, Lianjie; Williams,
Michael U.; and Tan, Xi, "Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation:
Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K
Oral Anticoagulants" (2018). Clinical and Translational Science Institute. 11.
https://researchrepository.wvu.edu/ctsi/11

This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has
been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The
Research Repository @ WVU. For more information, please contact ian.harmon@mail.wvu.edu.

Authors
Xue Feng, Usha Sambamoorthi, Kim Innes, Gregory Castelli, Traci LeMasters, Lianjie Xiong, Michael U.
Williams, and Xi Tan

This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/ctsi/11

HHS Public Access
Author manuscript
Author Manuscript

Cardiovasc Drugs Ther. Author manuscript; available in PMC 2019 December 01.
Published in final edited form as:
Cardiovasc Drugs Ther. 2018 December ; 32(6): 591–600. doi:10.1007/s10557-018-6825-7.

Predictors of Major Bleeding Among Working-Age Adults with
Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug
Interactions and Switching from Warfarin to Non-vitamin K Oral
Anticoagulants

Author Manuscript

Xue Feng1, Usha Sambamoorthi1, Kim Innes2, Gregory Castelli3, Traci LeMasters1, Lianjie
Xiong4, Michael U. Williams5, and Xi Tan1
1Department

of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia
University, Morgantown, WV, USA

2Department

of Epidemiology, School of Public Health, West Virginia University, Morgantown, WV,

USA
3University
4College

of Pittsburgh Medical Center (UPMC) St. Margaret, Pittsburgh, PA, USA

of Pharmacy, California Health Sciences University, Clovis, CA, USA

5Department

of Medicine, San Antonio Military Medical Center, San Antonio, TX, USA

Abstract
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Purpose—This study aims to evaluate the associations between switching from warfarin to nonvitamin K oral anticoagulants (NOACs), exposure to potential drug-drug interactions (DDIs), and
major bleeding events in working-age adults with atrial fibrillation (AF).
Methods—We conducted a retrospective cohort study using the claims database of commercially
insured working-age adults with AF from 2010 to 2015. Switchers were defined as patients who
switched from warfarin to NOAC; non-switchers were defined as those who remained on warfarin.
We developed novel methods to calculate the number and proportion of days with potential DDIs
with NOAC/warfarin. Multivariate logistic regressions were utilized to evaluate the associations
between switching to NOACs, exposure to potential DDIs, and major bleeding events.

Author Manuscript

Results—Among a total of 4126 patients with AF, we found a significantly lower number of
potential DDIs and the average proportion of days with potential DDIs in switchers than nonswitchers. The number of potential DDIs (AOR 1.14, 95% CI 1.02–1.27) and the HAS-BLED
score (AOR 1.64, 95% CI 1.48–1.82) were significantly and positively associated with the
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likelihood of a major bleeding event. The proportion of days with potential DDIs was also
significantly and positively associated with risk for bleeding (AOR 1.42, 95% CI 1.03, 1.96). We
did not find significant associations between switching to NOACs and major bleeding events.
Conclusions—The number and duration of potential DDIs and patients’ comorbidity burden are
important factors to consider in the management of bleeding risk in working-age AF adults who
take oral anticoagulants.
Keywords
Drug-drug interactions; Atrial fibrillation; Bleeding; Switching; Non-vitamin K oral
anticoagulants

Introduction
Author Manuscript

The number of atrial fibrillation (AF) diagnoses has been growing in the United States (US)
and is estimated to increase to 12.1 million in 2030 [1].Adults who are 40 years of age and
older have a lifetime risk of 25% to develop AF [2]. According to the most recent guidelines
published by the American College of Cardiology (ACC) and the American Heart
Association (AHA), AF patients with a high risk of stroke should be treated with oral
anticoagulants, for example, warfarin [3], as well as non-vitamin K oral anticoagulants
(NOACs) that have been approved by the US Food and Drug Administration for patients
with AF since 2010 [4].

Author Manuscript

Warfarin is known to interact with numerous drugs and foods, and the list of interactions
continues to expand [5]. A large number of drug-drug interactions (DDIs) with warfarin
were reported to increase the international normalized ratio (INR) and risk of hemorrhage
[5–8]. NOACs are also known to interact with quite a number of drugs that increase the risk
of bleeding, which includes prescription medications frequently taken along with NOACs by
patients with AF, such as rhythm control medications (e.g., amiodarone) [9, 10]. However,
the fewer number of drug-drug and drug-food interactions are considered major advantages
of NOACs, as compared with warfarin. Yet, the burden of potential DDIs with NOACs has
not been well studied in patients with AF. On the other hand, current clinical guidelines thus
recommend AF patients on anticoagulant therapy be evaluated for risk of bleeding using the
HAS-BLED index [3, 11]. However, potential DDIs with oral anticoagulants are not
included in the design of the HAS-BLED index [3]. To date, no population-based studies
have investigated the burden of DDIs among patients with AF on anticoagulant therapy and
the influence of DDIs on bleeding events in these patients.

Author Manuscript

In addition to a decreased risk of DDIs with NOACs, another major advantage is that NOAC
users, in contrast to patients on warfarin, do not require routine blood monitoring. This may
help explain why many working-age adults switch to NOACs, for example, to avoid missed
time at work due to the frequent doctor visits associated with warfarin therapy. When
compared to warfarin, NOACs showed the favorable or noninferior effectiveness and safety
profiles in most clinical trials and recent observational studies [12–17]. A 2017 study in AF
patients of all ages revealed that those who switched from warfarin to dabigatran were
significantly more likely to suffer gastrointestinal (GI) bleeding, but were significantly less
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likely to experience intracranial bleeding, than persistent warfarin users [18]. However,
population-based studies have not assessed safety outcomes in working-age AF patients who
switch from warfarin to NOACs, known to have a lower risk of DDIs than warfarin.
Therefore, the objective of this study was to evaluate the associations between switching to
NOACs, exposure to potential DDIs, and major bleeding events in this population.

Methods
Conceptual Framework

Author Manuscript

To guide the study design and the selection of variables, we utilized Andersen’s behavioral
model for health service use [19]; this model includes (1) predisposing factors (e.g.,
demographics, pre-existing conditions, and other factors that may influence patient use of
health care and services), (2) enabling factors (e.g., insurance and other factors related to
health care access), and (3) need factors that reflect patients’ disease severity and overall
health condition.
Study Design
This retrospective cohort study used commercial insurance claims data between January
2010 and December 2015 to compare the incidence of major bleeding between switchers
and non-switchers and to assess the influence of potential DDIs on bleeding risk. The index
date was defined as the initial date of NOAC or warfarin prescription for the switcher and
the non-switcher, respectively. The baseline period was defined as 183 days (6 months) prior
to the index date, the assessment period was defined as 183 days after the index date, and the
follow-up period was defined as 183 days following the assessment period.

Author Manuscript

Data Source
We used an adjudicated claims database of commercially insured individuals. The database
includes medical, pharmacy, and enrollment data. It is similar in age and gender to the US
commercially insured census population for individuals less than 65 years of age. This data
is made available through a license to IQVIA’s Real World Data: Adjudicated Claims - US
(also known as PharMetrics Plus), 10% sample January 2006–December 2015.
Study Sample

Author Manuscript

Patients were included in our study if they (1) had the first observed oral anticoagulant date
(the index date) between 2010 and 2014; (2) were diagnosed with AF; (3) were continuously
enrolled in a health plan during the baseline, assessment, and the follow-up periods; and (4)
were aged between 18 and 63 years at the index date (we restricted patients’ age 63 to
account for the 1-year follow-up period). Patients who switched to warfarin/NOACs during
the assessment or follow-up period were excluded (Fig. 1).
Measures
Dependent Variable—Major bleeding events (yes/no) during the follow-up period were
identified by at least one diagnosis code (the ICD-9-CM codes and ICD-10-CM codes) from
the inpatient or outpatient claims provided by the data source (Appendix. Table 1).

Cardiovasc Drugs Ther. Author manuscript; available in PMC 2019 December 01.

Feng et al.

Page 4

Key Independent Variables

Author Manuscript

Switching from Warfarin to NOACs: Switchers were defined as patients who switched
from warfarin to NOAC, and we operationalized the definition as having at least one
prescription of warfarin at the baseline as well as no prescription of warfarin in the
assessment and the follow-up periods. Non-switchers refer to those who only took warfarin
during our study period. They were identified as having no NOACs in any observed study
period.

Author Manuscript

Potential Drug-Drug Interactions: Potential DDIs were defined as the concomitant use of
medications that can result in clinically significant interactions with warfarin (e.g.,
simvastatin) or NOACs (e.g., itraconazole for dabigatran, clarithromycin for rivaroxaban,
and vortioxetine for apixaban) as per IBM Micromedex® Drug Interaction Checking [20].
We calculated the potential DDI burden as the number of potential DDIs and the proportion
of days with potential DDIs.
Number of Potential DDIs: The number of potential DDIs was defined as the highest
observed number of potential DDIs in a single day during the assessment period (Fig. 2). In
other words, we obtained the number of potential DDIs for each day of the assessment
period and used the highest value as the number of potential DDIs. In our calculations, we
required at least a 1-day overlap of warfarin or NOAC use and consumption of medications
with the potential to interact with these anticoagulants (potential DDIs) based on
prescription claim data. This measure of potential DDIs is thought to reflect the cumulative
effects of concomitant medication use with oral anticoagulants.

Author Manuscript

Proportion of Days with Potential DDIs: We also calculated the proportion of days with
potential DDIs by dividing the number of days of potential DDIs (i.e., concomitant use of
oral anticoagulant therapy with medications that can lead to clinically relevant drug
interactions) by the length of the assessment period, as presented below:
Proportion of days with potential DDIs
the number of days with potential DDIs
=
the number of days of the assessment period

When we counted the number of days with potential DDIs, we required concomitant (same
day) use of oral anticoagulants in combination with medications likely to interact with these
specific anticoagulants based on the prescription claim data. The proportion of days with
potential DDIs thus reflects the simultaneous use of and duration of exposure to these
potential DDIs.

Author Manuscript

Other Independent Variables: We included (1) predisposing factors (gender, age at index
date, geographic region of residence), (2) enabling factors (type of healthcare plan), and (3)
need factors. Need factors included adherence to the warfarin/NOACs, measured by the
proportion of days covered (PDC) during the assessment period [21]; and medical history,
including prior ischemic stroke/transient ischemic attack (TIA), prior cardioembolic
complications (ischemic stroke, TIA, systemic embolism, and myocardial infarction), and
scores of CHA2DS2-VASc [3] index and HAS-BLED index (hypertension, prior stroke, prior
Cardiovasc Drugs Ther. Author manuscript; available in PMC 2019 December 01.
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major bleeding, liver disease, renal disease, labile INR, age > 65, concomitant medication
use, and alcohol abuse) [11], which measured the risk of ischemic stroke and major
bleeding, respectively. We also calculated the number of chronic conditions (arthritis,
asthma, cancer, COPD, dementia, depression, diabetes, hyperlipidemia, hepatitis, HIV,
osteoporosis, schizophrenia, and substance abuse disorders) based on the framework used by
the US Department of Health and Human Services, which were not included in the
CHA2DS2-VASc or HAS-BLED indexes [22]. We did not include antiplatelet or
nonsteroidal anti-inflammatory drug (NSAIDs) use and data of labile INR in the calculation
for the HAS-BLED score. Because antiplatelet and NSAID use was captured in the exposure
to DDIs and information of labile INR was not observable in the data source. All conditions
were identified during the baseline and assessment periods. Additionally, we measured the
potential DDIs with rhythm control medications (yes/no) because AF patients commonly use
these drugs.

Author Manuscript

Statistical Analyses
In univariate analyses, we used chi-squared tests to analyze the associations between the
outcome variables and the categorical independent variables. We performed the two-sample t
tests or Wilcoxon signed-rank tests for the continuous variables. We used multivariate
logistic regression to assess the association of switching to NOACs and potential DDIs to
bleeding risk, controlling for the other independent variables. We also performed subgroup
analyses by only focusing on hemorrhagic stroke, intracranial hemorrhage, and
gastrointestinal hemorrhage for the dependent variables.

Author Manuscript

Secondary Analyses—To control selection bias, we used the inverse probability of
treatment weighting (IPTW) in our secondary analyses, which balanced the switchers and
non-switchers and minimized the observed selection bias because of potential confounders,
including the HAS-BLED score, the CHA2DS2-VASc score, number of chronic conditions,
sex, gender, geographical regions, and type of health insurance.

Author Manuscript

In addition, we utilized a random forest prediction model to identify the leading predictors
of major bleeding in the study sample. Random forest is a machine learning method often
used for predictive accuracy, which has been applied in health outcome research in recent
years [23–25]. As compared with traditional statistical analyses, random forest prediction is
suitable for high-dimension variable selection and can be used to target the AF patients at
higher risk for major bleeding. In the random forest regression, we randomly split the
original data into two parts: (1) a training dataset with 60% of the original sample and (2) a
validation dataset with the remaining 40% of the original sample. Collection of classification
trees was built from bootstrap samples of data and variables. The performance of the
predictive model was evaluated using the area under the receiver operating characteristic
curve (AUC). SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and R programming language
(version 3.3.3; R Foundation, Vienna, Austria) were used for the analyses.

Results
A total of 4126 AF patients met the inclusion criteria in this study. Demographic
characteristics, clinical profiles, and medication-related information are presented in Table 1.
Cardiovasc Drugs Ther. Author manuscript; available in PMC 2019 December 01.
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Patients were predominantly male (70.2%), with the majority living in South (33.5%) or
Mid-West (33.9%); most were identified as non-switchers (88.3%). Patient age averaged
55.6 years (SD = 7.2). The average number of potential DDIs was 1.09 days (SD = 1.01,
range = 0 to 7), and the mean proportion of days with potential DDIs averaged was 0.30 (SD
= 0.34, range = 0 to 1) in the assessment period.
A significantly lower number of potential DDIs in switchers than non-switchers were found
(0.51 ± 0.74 vs.1.17 ± 1.02, p < 0.0001). The average proportion of days with potential
DDIs was also lower among switchers than among non-switchers (0.22 ± 0.34 vs. 0.31
± 0.34, p < 0.0001), suggesting a lower burden of potential DDIs among the switchers. The
most commonly used medications that could result in a DDI were simvastatin (20.5%)
among non-switchers and rhythm control medication (15.6%) among switchers (data not
presented).

Author Manuscript

A total of 360 AF patients had major bleeding events in the follow-up period. The univariate
analysis (Table 2) did not demonstrate a significant association between switching and major
bleeding (p = 0.50). However, the number of potential DDIs and the proportion of days with
potential DDIs were significantly and positively associated with major bleeding events (p <
0.0001 for both variables). Other factors significantly associated with the major bleeding
included female gender, older age, types of health insurance, history of stroke/TIA,
cardioembolic complications, renal disease, liver disease, hypertension, and prior bleeding
events; in addition, number of chronic conditions, CHA2DS2-VASc score, and HAS-BLED
score were also significantly and positively associated with the occurrence of major bleeding
(Table 2).

Author Manuscript
Author Manuscript

Because of significant multicollinearity between the two measures of exposure to DDIs in
this study, we present the results from two multivariate logistic regression models (Table 3).
Switching to NOACs was not significantly related to bleeding risk in any models. In model
1, the factors significantly and positively associated with the likelihood of a major bleeding
event included the number of potential DDIs (AOR 1.14, 95% CI 1.02–1.27) and HASBLED score (AOR 1.64, 95% CI 1.48–1.82), as well as female sex, older age, and having
health insurance of preferred provider organization versus other types of insurance. In model
2, the proportion of days with potential DDIs was significantly and positively associated
with risk for bleeding (AOR 1.42, 95% CI 1.03, 1.96), and the other significant associations
in model 1 remained. Additionally, because of collinearity between the number of chronic
conditions, the CHA2DS2-VASc score, and the HAS-BLED score, we added the number of
chronic conditions and the CHA2DS2-VASc score into the models separately without the
HAS-BLED score. Significant positive associations between the number of chronic
conditions, the CHA2DS2-VASc score, and the major bleeding events were found in the
adjusted models, and the other results were similar to model 1 and model 2.
In the secondary analyses, the association between switching to NOACs and major bleeding
events remained insignificant after applying IPTW (data not presented). To evaluate the
interactions between multiple variables and to examine the relative importance of variables
as predictors of major bleeding, we performed additional analyses using the random forest
prediction model. As illustrated in Fig. 3, the HAS-BLED score was the most important
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predictor for major bleeding, followed by prior major bleeding, the proportion of days with
potential DDIs, prior stroke events, and the number of potential DDIs. Switching from
warfarin to NOAC did not appear to be a significant predictor of major bleeding. The AUC
for the model was 0.67, indicating a fair prediction.
In the subgroup analyses, the associations between key independent variables and major
bleeding events (i.e., hemorrhagic stroke, intracranial hemorrhage, and gastrointestinal
hemorrhage) remained significant. However, we did not find significant associations
between the other independent variables (i.e., sex, age, health insurance types) and major
bleeding events based on the results of multivariate logistic regression models. Similar
findings were also observed in the random forest prediction model in the subgroup analysis.

Discussion
Author Manuscript

To our knowledge, this is the first population-based study to examine the influence of
switching from warfarin to NOACs and potential DDI exposure on the bleeding risk in the
US working-age population with AF. Both measures of exposure to potential DDI (i.e., the
number of potential DDIs and the proportion of days with potential DDIs) were significantly
and positively associated with risk for major bleeding events among the working-age adults
with AF. On the other hand, no significant associations between switching from warfarin to
NOACs and major bleeding events were observed in our analyses. In addition, the HASBLED score was an important predictor of major bleeding risk, showing a stronger
association with risk for major bleeding events.

Author Manuscript

Interestingly, exposure to potential DDI was an independent predictor of risk for major
bleeding and was identified as an important predictor in the random forest prediction model.
However, switching from warfarin to NOACs was not associated with major bleeding events.
Switching from warfarin to NOAC indicated a significantly lower potential DDI burden than
in those patients persistently treated with warfarin, although the burden was high in both
groups. Therefore, even though the patients’ burden of DDIs might decrease after switching
from warfarin to NOACs, the degree of bleeding risk reduction may not be substantial.
Furthermore, it is also possible that the non-significant association is a result of unobserved
selection bias and limited follow-up period, which requires further examinations to address
these issues.

Author Manuscript

AF management includes rate control, rhythm control, and prevention of thromboembolism
[3]. Both warfarin and NOACs have major interactions with rhythm control medications
such as amiodarone that may lead to bleeding complications. Although we found that DDIs
with rhythm control medications were very common in patients with NOACs, we did not
find a significant association between concomitant use of these agents and major bleeding
events. According to the 2014 AHA/ACC/HRS and the 2010 European Society of
Cardiology guidelines, there is no indication to reduce the dosage of dabigatran in patients
taking amiodarone; however, the cumulative effects from other drug interactions may still
elevate the risk of hemorrhage [3, 10]. Given the current incomplete knowledge regarding
NOAC interactions and the lack of specific reversal agents for all NOAC agents except
dabigatran, large prospective studies regarding the safety of co-administration of NOACs
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and medications that may lead to DDIs are needed for risk prevention and management
strategies for AF patients on oral anticoagulant therapy.
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Overall, our findings suggest both comorbid conditions and potential DDIs are important
predictors of major bleeding. In the secondary analyses, the HAS-BLED index, the number
of potential DDIs, and the proportion of days with potential DDIs were identified among the
top five predictors of major bleeding. This suggests that models of predicting major bleeding
events should include information on potential DDIs for increased accuracy and precision.
On the other hand, given the fair performance of prediction models, the risk for major
bleeding may be affected by multiple factors, including but not limited to comorbid
conditions and concomitant medications use measured in this study. The sex difference on
major bleeding was probably because we included postmenopausal bleeding events, and this
significant association disappeared when only hemorrhagic stroke, intracranial hemorrhage,
and gastrointestinal hemorrhage were considered for the major bleeding.

Author Manuscript

Based on our findings, clinicians should consider all potential DDIs linked to the increased
risk of hemorrhage in the management of patients on anticoagulation therapy. A recent
single-center study utilizing a comprehensive protocol to manage significant antimicrobial
DDIs with warfarin (e.g., to document significant DDIs and duration of interaction in
progress notes and discharge summary notes) demonstrated a significant reduction in
bleeding events [26]. Utilizing computerized drug interaction surveillance systems can be
helpful in improving management of issues related to DDIs [27]. However, the current
design of these electronic systems allows only for simple warnings regarding each potential
DDI. Current surveillance systems do not take into account the effects of cumulative
exposure to DDIs, nor important patient characteristics such as comorbidities and disease
severity. Thus, limitations of current drug interaction surveillance systems may reduce their
utility in clinical practice. The continued development of DDI surveillance software is
needed to provide more detailed and patient-specific management options [28]. Furthermore,
a recent study demonstrated that e-health-based coagulation service, which comprised
electronic health records and computer-assisted patient care, was associated with fewer
adverse events in patients taking oral anticoagulants [29]. Thus, we recommend optimizing
the anticoagulation management services by adopting health technology that incorporates
the summarized information of potential DDIs and comorbid conditions to improve
collaborative care for patients with AF.

Author Manuscript

We had several limitations in this study. First, we did not include all possible DDIs (i.e., the
moderate and mild DDIs) in our analyses, and we only assessed the encounter of potential
DDIs in a limited length of time using conservative measures. Hence, the prevalence of
potential DDIs may be underestimated. Secondly, we did not capture the labile INR and
actual alcohol use in the HAS-BLED index due to the limited data availability. But, INR
does not apply to NOAC users, and it may confound the comparison between warfarin and
NOACs in this study. Thirdly, prescription drug claims used in the study may not reflect the
actual use of medications in patients, for example, if they discontinued OAC treatment. In
addition, we assessed NOACs as a group in analyses. Each NOAC may have different safety
and DDI profiles, which warrants further longitudinal studies to look into the specific agents
in this drug class. Given that our definitions for the switcher and non-switchers were based
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on arbitrarily classified study periods, our findings may not apply to patients who frequently
changed their oral anticoagulant therapies or patients who were identified as multiple
switchers in our study period. Due to our study design, we may not capture detailed
information regarding time-to-major bleeding events. Additionally, our findings were limited
to US working-age adults with AF. The applicability to other populations (e.g., older
patients or patients from countries outside the US) needs to be explored by future research.
Lastly, our study may exclude patients who died before switching from warfarin to NOACs,
which might introduce immortal time bias.

Author Manuscript

This study has several strengths. First, our investigation employed a novel approach
measuring DDI burden, allowing capture of two important aspects of DDIs—the number of
drugs used in combination with oral anticoagulants that may result in DDIs (the number of
potential DDIs) and the cumulative duration of drug exposure (the proportion of days with
potential DDIs). Another major strength of this study is that we used an algorithmic model
to evaluate the robustness of our statistical findings and to identify the most important
predictors of bleeding risk. Also, we used an advanced statistical method, IPTW, to control
observed selection bias. Moreover, this study used a population-based design and a
nationally representative sample of commercially insured US working-age adults:
incorporating typical prescribing patterns and clinical settings in the US. Our study findings
have implications directly relevant to real-world practice and settings.

Conclusions

Author Manuscript

Concomitant use of drugs known to interact adversely with oral anticoagulant therapy was
common in working-age US adults with AF. Those who switched from warfarin to NOACs
had a significantly lower DDI burden than did those who remained on warfarin. The number
of potential DDIs and proportion days with DDIs were significant and independent
predictors of bleeding risk, as were HAS-BLED scores. However, switching from warfarin
to NOACs did not predict bleeding risk. Collectively, these findings suggest that potential
DDIs and patients’ comorbidity burden are important factors to consider in the management
of bleeding risk in working-age AF adults who take oral anticoagulants. We recommend
developing DDI surveillance systems and highlighting serious DDIs in the AF guideline to
better inform clinicians and patients.

Supplementary Material
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Flow chart to obtain the final study sample
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Study design and periods to identify the key independent variables and dependent variable.
DDIs: drug-drug interactions; IV: independent variable; DV: dependent variable; NOAC:
non–vitamin K oral anticoagulant
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Fig. 3.
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Important predictors of major bleeding events in working-age adults with atrial fibrillation
who were treated with oral anticoagulants (random forest prediction model) Note: AUC =
0.67, accuracy = 91.2%. AUC, the area under the receiver operating characteristic curve;
DDIs, drug-drug interactions; NOACs, non–vitamin K oral anticoagulants; OAC, oral
anticoagulants; PDC, proportion days covered.
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515 (12.5%)

Other

Stroke/TIA in the baseline or assessment period

Yes

No

Major bleeding in the baseline or assessment period

Medical history

869 (21.1%)

3257 (78.9%)

3073 (74.5%)

PPO

Need factors

538 (13.0%)

HMO

Insurance type

Enabling factors

55.59 ± 7.15

1382 (33.5%)

Age

1015 (24.6%)

Mid-West

2898 (70.2%)

1228 (29.8%)

East

Patient region

Male

Female

Sex

Predisposing factors

1228 (29.8%)

0.30 ± 0.34

Other independent variables

1.09 ± 1.01

Proportion of days with potential DDIs

481 (11.7%)

Yes

Exposure to potential DDIs Number of potential DDIs

3645 (88.3%)

No

Switched from warfarin to NOACs No

Key independent variables

N (%)/mean ± SD

Descriptive statistics of working-age adults with atrial fibrillation who were treated with oral anticoagulants (N = 4126)
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391 (9.5%)

426 (10.3%)

1.40 ± 1.12
1.27 ± 0.96

Number of chronic conditions in the baseline or assessment period

HAS-BLED score in the baseline or assessment period

DDI, drugDDI-drug interaction; HMO, health maintenance organization; NOACs, non–vitamin K oral anticoagulants; OAC, oral anticoagulants; PDC, proportion days covered; PPO, preferred provider
organization; SD, standard deviation; TIA, transient ischemic attack

1.90 ± 1.25

CHA2DS2-VASc in the baseline or assessment period

Health status

0.74 ± 0.28

616 (14.9%)

Yes

OAC adherence (PDC) in the assessment period

3510 (85.1%)

No

Having DDI with rhythm control medications

Medication profile

3700 (89.7%)

Yes

455 (11.0%)

No

Liver disease in the baseline or assessment period

Yes

No

3671 (89.0%)

1109 (26.9%)

Renal disease in the baseline or assessment period

3017 (73.1%)

Yes

659 (16.0%)

No

Hypertension in the baseline or assessment period

Yes

No

3467 (84.0%)

3735 (90.5%)
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Yes

Author Manuscript

Cardio-embolic complications event in the baseline or assessment period
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No
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1382
1398
331

South

West

455 (12.0%)

3073
515

Need factors

Other

2823 (75.0%)

538

PPO

488 (13.0%)

302 (8.0%)

1264 (33.5%)

1275 (33.9%)

925 (24.6%)

HMO

Health insurance type

Enabling factors

1015

2678 (92.4%)

2898

Mid-West

1088 (88.6%)

1228

East

Regions

Male

Female

Sex

Age

Predisposing factor

55.46± 7.21

0.29 ± 0.34

Other independent variables

1.07 ± 0.99

443 (92.1%)

481

Proportion of days with potential DDIs

3323 (91.2%)

3645

60 (16.7%)

250 (69.4%)

50 (13.9%)

29 (8.1%)

134 (37.2%)

107 (29.7%)

90 (25.0%)

220 (7.6%)

140 (11.4%)

56.91 ± 6.35

0.37 ± 0.35

1.37 ± 1.14

38 (7.9%)

322 (8.8%)

360

3766

Number of potential DDIs

Exposure to potential DDIs

Yes

No

Switched to NOACs

Key independent variables

Yes

No

Major bleeding in the follow-up period N (%)/mean (SD)

0.03

0.39

< 0.0001

< 0.0001

< 0.0001

< 0.0001

0.50

p value

Factors associated with major bleeding in working-age adults with atrial fibrillation who were treated with oral anticoagulants—univariate analyses (N =
4126)
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1.87 ± 1.23
1.22 ± 0.93

CHA2DS2-VASc score

HAS-BLED score

1.79 ± 1.11

2.27 ± 1.31

1.80 ± 1.30

0.76 ± 0.26

59 (9.6%)

301 (8.6%)

57 (13.4%)

303 (8.2%)

74 (16.3%)

286 (7.8%)

282 (9.3%)

78 (7.0%)

75 (11.4%)

285 (8.2%)

49 (12.5%)

311 (8.3%)

171 (19.7%)

189 (5.8%)

< 0.0001

< 0.0001

< 0.0001

0.13

0.42

0.0003

< 0.0001

0.02

0.0008

0.005

< 0.0001

DDI, drug-drug interaction; HMO, health maintenance organization; NOACs, non–vitamin K oral anticoagulants; OAC, oral anticoagulants; PDC, proportion days covered; PPO, preferred provider
organization; SD, standard deviation

1.37 ± 1.10

0.74 ± 0.28

557 (90.4%)

Number of chronic conditions

Health status

OAC PDC

Yes

3209 (91.4%)

303 (86.6%)

426

3510

3397 (91.8%)

No

DDI with rhythm control medication

Medication profile

Yes

No

381 (83.7%)

3385 (92.2%)

3700

455

Liver disease in the baseline or assessment period

3671

2735 (90.7%)

3017

Yes

1031 (93.0%)

No

Renal disease in the baseline or assessment period

Yes

No

584 (88.6%)

3182 (91.8%)

1109

659

Hypertension in the baseline or assessment period

3467

342 (87.5%)

391

Yes

3424 (91.7%)

No

Cardioembolic complications event in the baseline or assessment period

Yes

No

189 (80.3%)

3068 (94.2%)

3735

869

Yes

Stroke in the baseline or assessment period

3357

No

Major bleeding events in the baseline or assessment period
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Factors associated with major bleeding in working-age adults with atrial fibrillation who were treated with oral
anticoagulants—multivariate logistic regressions (N = 4126)
Model 1

Model 2

AOR (95%CI)

p value

AOR (95%CI)

p value

Female vs. male

1.74 (1.34, 2.26)

0.0004

1.74 (1.34, 2.25)

< 0.0001

Age

1.03 (1.01, 1.05)

0.0008

1.03 (1.01, 1.05)

0.003

East vs West

0.85 (0.53, 1.34)

0.47

0.84 (0.53, 1.33)

0.45

Mid-West vs West

0.75 (0.48, 1.16)

0.19

0.75 (0.48, 1.15)

0.18

South vs West

1.07 (0.70, 1.65)

0.76

1.07 (0.70, 1.65)

0.75

HMO vs other

0.76 (0.51, 1.15)

0.19

0.75 (0.50, 1.12)

0.16

PPO vs other

0.63 (0.46, 0.87)

0.004

0.62 (0.45, 0.86)

0.004

Switcher vs non-switcher

1.01 (0.70, 1.46)

0.96

0.94 (0.66, 1.35)

0.75

Proportion of days with potential DDIs

–

–

1.42 (1.03, 1.96)

0.03

Number of potential DDIs

1.14 (1.02, 1.27)

0.02

–

–

HAS-BLED score

1.64 (1.48, 1.82)

< 0.0001

1.67 (1.51, 1.85)

< 0.0001

Predisposing factors
Sex

Region
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AOR, AOR, adjusted odds ratio; DDI, drug-drug interaction; HMO, health maintenance organization; PDC, proportion days covered; PPO,
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